No­vo Nordisk’s GLP-1/amylin com­bo drug Ca­griSe­ma was not as good as Eli Lil­ly’s mar­ket­ed obe­si­ty shot Zep­bound in a head-to-head study, the Dan­ish com­pa­ny said Mon­day...